ImmunoGen Announces Webcasts of Presentations at Upcoming Investor Conferences
03 February 2017 - 9:00AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that the following presentations by Company
management at upcoming investor conferences will be webcast:
- Leerink Partners 6th
Annual Global Healthcare ConferenceFebruary 15, 2017 at
1:00pm ET
- 2017 RBC Capital Markets Global
Healthcare ConferenceFebruary 23, 2017 at 9:30am ET
- Cowen and Company 37th
Annual Health Care ConferenceMarch 7, 2017 at 8:40am ET
The webcasts will be accessible live through the “Investors”
section of the Company’s website, www.immunogen.com; a replay will
be available at the same location for approximately a week.
About ImmunoGenImmunoGen is a clinical-stage
biotechnology company that develops targeted cancer therapeutics
using its proprietary antibody-drug conjugate technology.
ImmunoGen’s lead product candidate, mirvetuximab soravtansine, is
in a Phase 3 trial for folate receptor alpha (FRα)-positive
platinum-resistant ovarian cancer, and is in Phase 1b/2
testing in combination regimens for earlier-stage disease.
ImmunoGen’s ADC technology is used in Roche’s marketed product,
Kadcyla®, in three other clinical-stage ImmunoGen product
candidates, and in programs in development by partners Amgen,
Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. More
information about the Company can be found at
www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170202006257/en/
Investor Contact:ImmunoGen, Inc.Sarah Kiely,
781-895-0600sarah.kiely@immunogen.comorMedia
Contacts:ImmunoGen, Inc.Amy Reilly,
781-895-0138amy.reilly@immunogen.comorFTI Consulting Inc.Robert
Stanislaro, 212-850-5657robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Sep 2023 to Sep 2024